Dr. Mehdi Mirsaeidi, MD

Dr. Mirsaeidi practices at UF Health Rehabilitation Hospital - North in Jacksonville, Florida, part of UF Health.

Dr. Mirsaeidi's NPI, 1285961680, was assigned on November 6, 2009. Dr. Mirsaeidi graduated from Other in 1993. Dr. Mirsaeidi holds Florida license ME 124903.

Dr. Mirsaeidi's primary practice is UF Health Rehabilitation Hospital - North, at 15255 Max Leggett Pkwy, 2nd and 3rd Floors, Jacksonville, FL 32218 in Duval County. The practice phone is (904) 456-8001.

Dr. Mirsaeidi's primary practice is UF Health Rehabilitation Hospital - North in Jacksonville, Florida, part of UF Health. Dr. Mirsaeidi is also affiliated with UF Health Jacksonville. The medical group on file is University of Miami Health System. Dmand AI also links Dr. Mirsaeidi to 3 more medical groups and 1 ambulatory surgery center, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Mirsaeidi practices, 3 sites in all. Vendor and product names are available with a free account.

Pulmonary disease is Dr. Mirsaeidi's primary specialty in the NPI Registry, under taxonomy code 207RP1001X. Dr. Mirsaeidi is board certified in critical care medicine by the American Board of Internal Medicine. Dmand AI has Dr. Mirsaeidi's licenses on file in 3 states: Florida, Illinois and District of Columbia.

CMS data shows 337 Medicare services from Dr. Mirsaeidi across 8 procedure codes in 2024, for 182 Medicare patients. Medicare paid $34,613 for them.

CMS counts 182 Medicare patients who saw Dr. Mirsaeidi in 2024. The largest group is 65 to 74, with 85 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 36% are also on Medicaid. Their average risk score is 2.62, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Mirsaeidi's median patient age at 69, with 63% women.

In 2024, Dr. Mirsaeidi wrote 344 Medicare Part D claims for 63 patients. 44% of them were for generic drugs. CMS names the drug for 258 of them, across 10 drugs with 11 or more claims each, at $72,158 in total drug cost. In 2023, CMS named 314 claims across 13 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 60 out of 100 for Dr. Mirsaeidi for performance year 2024, reported through an alternative payment model (APM). Dr. Mirsaeidi accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 230 papers to Dr. Mirsaeidi, published from 2005 to 2024. 2021 was the busiest year, with 30. The most frequent topics are Iran, COVID-19 and Nontuberculous Mycobacteria. Dr. Mirsaeidi has published most often in Front Med (Lausanne). Dr. Mirsaeidi's most frequent co-authors are Michael A. Campos, MD, Gregory E. Holt, MD and Dean E. Schraufnagel.

Dmand AI links Dr. Mirsaeidi to 2 clinical trials. Conditions studied include Mycobacterium Infections, Nontuberculous, Respiratory Distress Syndrome and COVID-19.

CMS Open Payments shows 104 general payments to Dr. Mirsaeidi from 17 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 53% of the total. Mallinckrodt LLC paid the most, $20,500.

Dmand AI lists 9 awards for Dr. Mirsaeidi, most recently Abstract Scholarship in 2014.

Dr. Mirsaeidi graduated from Other in 1993. Dr. Mirsaeidi is a member of ATS.

Dr. Mirsaeidi is in network with 14 carriers, including Aetna, Elevance and United Healthcare. HMO plans come from the most carriers, 8. Check the plan with the practice before a visit.